Hepatic Encephalopathy in Chronic Liver Disease

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric disturbances arising from chronic liver disease and cirrhosis. Central to its development is hyperammonaemia, resulting from impaired hepatic detoxification of ammonia produced by gut microbes and amino acid catabolism. Elevated ammonia crosses the blood–brain barrier, provoking astrocyte swelling, altered neurotransmission and cerebral oedema. Systemic inflammation and endotoxaemia further amplify neuroinflammatory cascades, leading to cognitive impairment, altered motor function and, in severe cases, coma. Clinically, HE ranges from minimal or covert forms, detectable only by specialised psychometric tests, to overt HE with obvious neurological deficits. Portal-systemic shunting and gut dysbiosis contribute to toxin accumulation and inflammatory signalling. Diagnosis relies on clinical assessment, serum ammonia measurement and, increasingly, neuroimaging and neurophysiological testing. Management combines ammonia-lowering therapies (lactulose, rifaximin), correction of precipitating factors and nutritional support. Emerging approaches target the gut–liver–brain axis, neuroinflammation and mitochondrial dysfunction. HE imposes a significant global burden, affecting quality of life, increasing hospital admissions and driving healthcare costs. Improved understanding of pathogenic mechanisms has sparked novel interventions aimed at modulating the microbiome, reducing systemic inflammation and protecting cerebral function.

Research from Nature Portfolio

Recent studies have elucidated the role of oxidative stress and gut microbial interactions in HE pathogenesis. In preclinical models, mitochondrial dysfunction in GABAergic neurons of the substantia nigra was shown to underpin motor deficits in toxin-induced HE. Targeted antioxidant therapy restored mitochondrial integrity, attenuated oxidative injury and reversed locomotor impairment, highlighting oxidative stress as a therapeutic target. In parallel, patient-based neuroimaging research has mapped the gut–liver–brain axis by combining stool microbiota profiling with magnetic resonance spectroscopy and diffusion tensor imaging. Specific bacterial taxa correlated with astrocytic changes, such as altered glutamine/glutamate ratios, and with neuronal integrity metrics, delineating distinct microbial drivers of astrocyte versus neuron dysfunction. This work substantiates the concept that dysbiosis and systemic inflammation converge to produce the neurochemical hallmarks of HE.

Hepatic Encephalopathy in Chronic Liver Disease publication trend

The graph below shows the total number of articles in hepatic encephalopathy in chronic liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Hyperammonaemia: Elevated blood ammonia due to impaired urea cycle function in the liver, leading to neurotoxicity.

Gut–liver–brain axis: The bidirectional network linking intestinal microbiota, hepatic metabolism and central nervous system function.

Neuroinflammation: Activation of glial cells and inflammatory mediators in the brain, contributing to neuronal dysfunction.

Minimal hepatic encephalopathy (MHE): Subclinical cognitive impairment in cirrhosis, detectable via specialised neuropsychometric testing.

Portal-systemic shunting: Diversion of portal venous blood into the systemic circulation, bypassing hepatic detoxification and promoting toxin influx to the brain.

References

1. The new digital era in decompensated cirrhosis. The Lancet Digital Health (2024).
2. Effects of oxidative stress on hepatic encephalopathy pathogenesis in mice. Nature Communications (2023).
3. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Scientific Reports (2016).
4. MR Imaging Findings in Hepatic Encephalopathy. American Journal of Neuroradiology (2008).
5. Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology (2014).
6. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of Hepatology (2021).
7. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. Journal of Hepatology (2022).